<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9804">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05689801</url>
  </required_header>
  <id_info>
    <org_study_id>2022-A01511-42</org_study_id>
    <nct_id>NCT05689801</nct_id>
  </id_info>
  <brief_title>Describe the Effect of the Optimized Hemodialysis Technique (HDx) With Medium Cut-Off Membrane on Recovery Time and Quality of Life</brief_title>
  <acronym>EHDXTRQV</acronym>
  <official_title>Pilot Study: Describe the Effect of the Optimized Hemodialysis Technique (HDx) With Medium Cut-Off Membrane on Recovery Time and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramsay Générale de Santé</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ramsay Générale de Santé</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the effect of optimizing the dialytic technique using simple questionnaires&#xD;
      carried out in clinical routine will be described.&#xD;
&#xD;
      More specifically, the conventional dialysis technique will be combined with biofeedback&#xD;
      software called HemoControl™. The recovery time and quality of life of patients who will use&#xD;
      a polyethersulfone membrane (Revaclear®) and a Medium Cut-Off (MCO) membrane (Theranova®)&#xD;
      will be observed.&#xD;
&#xD;
      The main objective is to describe the evolution of recovery time after a dialysis session in&#xD;
      conventional hemodialysis (HD) on Revaclear® membrane and in so-called optimized hemodialysis&#xD;
      (HDx) on MCO membrane, Theranova®.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2022</start_date>
  <completion_date type="Anticipated">January 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Result of the questionnaire &quot;recovery time after a dialysis session&quot;</measure>
    <time_frame>7 months</time_frame>
    <description>only one question : how long time recovering after a dialysis session (hours)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Terminal Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Patient on conventional hemodialysis then on optimized hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire &quot;recovery time after a dialysis session&quot;.</intervention_name>
    <description>A very short questionnaire just after the dialysis session</description>
    <arm_group_label>Patient on conventional hemodialysis then on optimized hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SF-12 questionnaire</intervention_name>
    <description>Questionnaire about quality of life of the patient</description>
    <arm_group_label>Patient on conventional hemodialysis then on optimized hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EQ-5D-5L Questionnaire</intervention_name>
    <description>Questionnaire about quality of life of the patient</description>
    <arm_group_label>Patient on conventional hemodialysis then on optimized hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pittman, John et McIntyre questionnaire</intervention_name>
    <description>Questionnaire about quality of life of the patient under dialysis</description>
    <arm_group_label>Patient on conventional hemodialysis then on optimized hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional hemodialysis</intervention_name>
    <description>patient on polyethersulfone membrane dialysis (Revaclear®, Baxter) with HemoControl™ for 12 weeks</description>
    <arm_group_label>Patient on conventional hemodialysis then on optimized hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Optimized hemodialysis</intervention_name>
    <description>patient on Medium Cut-Off membrane dialysis (Theranova®, Baxter) with HemoControl™ for 12 weeks.</description>
    <arm_group_label>Patient on conventional hemodialysis then on optimized hemodialysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient, male or female (using contraceptives, if of childbearing age), over 18 years&#xD;
             of age&#xD;
&#xD;
          -  Patient on conventional hemodialysis with synthetic membrane for at least 3 months&#xD;
&#xD;
          -  Patient with a recovery time after the dialysis session ≥ 4 hours&#xD;
&#xD;
          -  Informed patient who has signed a written consent to participate in the study&#xD;
&#xD;
          -  Affiliated patient or beneficiary of a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient whose seniority of dialysis is less than 3 months&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Protected patient: adult under guardianship, curatorship or other legal protection,&#xD;
             deprived of liberty by judicial or administrative decision&#xD;
&#xD;
          -  Patient with severe cognitive impairment&#xD;
&#xD;
          -  Medically unstable or frail patient&#xD;
&#xD;
          -  Patient who did not sign an informed consent form accepting this research (refusal of&#xD;
             consent or absence of signature).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guy Rostoker, Dr</last_name>
    <phone>01 69 39 92 00</phone>
    <email>rostotom@orange.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Privé Claude Galien</name>
      <address>
        <city>Quincy-sous-Sénart</city>
        <zip>91480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy ROSTOKER, Dr</last_name>
      <phone>01 69 39 92 00</phone>
      <email>rostotom@orange.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 22, 2022</study_first_submitted>
  <study_first_submitted_qc>January 10, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>January 10, 2023</last_update_submitted>
  <last_update_submitted_qc>January 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>terminal renal insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

